• About Us
      • Mission
      • Members
      • Board of Directors
      • Staff
      • Annual Meeting
    • Economic Impact
    • Issues
      • PAMA
      • Economic Impact of Clinical Labs
      • Protecting Access to Medicare Act
      • Laboratory Developed Tests
      • Reimbursement and Coverage
      • Patient Access to Lab Services
      • Value of Labs
      • IOAS Exception and Self-Referral
      • Regulatory Issues
      • Value of Health IT Data Standards
      • TRICARE Non-Coverage of LDTs
    • Take Action
    • News
      • ACLA Blog
      • ACLA Press Releases
      • Comments and Letters
      • ACLA In The News
    • Resources
    • Join Us
    • Home
    • Contact Us
    • Annual Meeting
ACLA
    • Home
    • Contact Us
    • Annual Meeting
  • About Us
    • Mission
    • Members
    • Board of Directors
    • Staff
    • Annual Meeting
  • Economic Impact
  • Issues
    • PAMA
    • Economic Impact of Clinical Labs
    • Protecting Access to Medicare Act
    • Laboratory Developed Tests
    • Reimbursement and Coverage
    • Patient Access to Lab Services
    • Value of Labs
    • IOAS Exception and Self-Referral
    • Regulatory Issues
    • Value of Health IT Data Standards
    • TRICARE Non-Coverage of LDTs
  • Take Action
  • News
    • ACLA Blog
    • ACLA Press Releases
    • Comments and Letters
    • ACLA In The News
  • Resources
  • Join Us

Protecting Access to Medicare Act

ACLA Files Appeal in ACLA v. Azar, Asks U.S. Court of Appeals to Address HHS’s Overreach in Data Reporting

December 04, 2018 Categories: Protecting Access to Medicare Act, Featured News, ACLA Press Releases

HHS’s continued flawed implementation of PAMA threatens beneficiaries’ access to critical lab services

Washington, D.C. – Today, the American Clinical Laboratory Association (ACLA) advanced its case against the U.S. Department of Health and Human Services’ (HHS) flawed and harmful implementation of the Protecting Access to Medicare Act (PAMA). ACLA’s opening brief argues that HHS has exceeded its statutory authority, circumventing Congress’ stated directive of establishing a market-based reimbursement model for laboratory services.

ACLA initially filed its lawsuit against HHS in 2017. Since then, ACLA and various stakeholders—including organizations representing patients, health care professionals, laboratories and diagnostic manufacturers—have reiterated the ongoing harm caused by the Department’s attempt to exempt nearly 99 percent of the laboratory market from the data reporting requirements under PAMA.

As ACLA’s brief notes, the Secretary’s final rule ” violates Congress’s unambiguous statutory directive to collect data from any ‘laboratory’ that receives a majority of its Medicare revenues from the relevant fee schedules. Instead, the Secretary’s rule rewrites the statute’s majority-of-revenues test to take into account non-laboratory revenue and, through this rewrite, exempts virtually all hospital laboratories from the data-reporting requirements. Because hospital laboratories are significant participants in Medicare and compete with independent laboratories and physician office laboratories in the private market, the Secretary’s rule guarantees that the data collected does not reliably represent the private market as Congress intended.”

HHS’ statutory violation has serious consequences for millions of Medicare beneficiaries, particularly the most vulnerable, who rely on essential lab services to monitor and manage a range of chronic diseases. Laboratories, including those serving rural communities and homebound seniors, have been forced to reduce services and care for Medicare beneficiaries as a result of the flawed data collection process.

“It’s imperative that the Court puts a stop to the Secretary’s regulatory overreach,” Julie Khani, President of ACLA, said. “Seniors are bearing the direct harm from the Department’s continued reliance on a failed process that directly contradicts the stated goals of Congress in protecting beneficiaries’ Medicare lab benefits.”

While the Court reviews the appeal, it is imperative that Congress take immediate action to address the harm facing millions of seniors and their access to essential lab services. Congress must reform and modernize the Clinical Laboratory Fee Schedule to ensure that all patients can continue to access the lab services upon which they depend.

# # #

ACLA is a not-for-profit association representing the nation’s leading clinical and anatomic pathology laboratories, including national, regional, specialty, hospital, ESRD and nursing home laboratories. The clinical laboratory industry employs nearly 277,000 people directly, and generates over 115,000 additional jobs in supplier industries. Clinical laboratories are at the forefront of personalized medicine, driving diagnostic innovation and contributing more than $100 billion to the nation’s economy.

Print page / Save as PDF

News

  • Press Releases
  • Letters and Comments
  • ACLA in the News

Issues

  • Economic Impact of Clinical Labs
  • Protecting Access to Medicare Act
  • Laboratory Developed Tests
  • Reimbursement and Coverage
  • Patient Access to Lab Services
  • Value of Labs
  • Regulatory Issues
  • Value of Health IT Data Standards
  • TRICARE Non-Coverage of LDTs

Fact Sheets

  • Value of Labs
  • Threats to Lab Services
  • Impacts of HHS’ Cuts to Lab Services

Media Contact

Grace Montgomery
Phone: (202) 499 2050
Email: press@acla.com

Back To Top

menu1

  • Economic Impact of Clinical Labs
  • Value of Lab Testing
  • Take Action
  • Join Us
  • Members
  • Contact Us

About Us

  • Mission
  • Members
  • Board of Directors
  • Staff
  • Annual Meeting

Issues

  • Economic Impact of Clinical Labs
  • Protecting Access to Medicare Act
  • Laboratory Developed Tests
  • Reimbursement and Coverage
  • Patient Access to Lab Services
  • Value of Labs
  • Regulatory Issues
  • Value of Health IT Data Standards
  • TRICARE Non-Coverage of LDTs

News

  • ACLA In The News
  • ACLA News
  • ACLA Press Releases
  • Comments and Letters
  • ACLA Blog

Address

202-637-9466
American Clinical Laboratory Association
1100 New York Ave, NW, Suite 725 West
Washington, DC 20005 USA
ACLA